罗米普洛斯蒂姆
医学
血小板生成素
临床试验
埃尔特罗姆博帕格
重症监护医学
血小板生成素受体
观察研究
血小板
并发症
兴奋剂
内科学
癌症
化疗
免疫疗法
血小板输注
肿瘤科
梅德林
药理学
药品
临床研究阶段
免疫学
作者
Hanny T. Al-Samkari,Gerald A. Soff
出处
期刊:Blood
[Elsevier BV]
日期:2026-07-06
卷期号:148 (12): 1534-1546
被引量:2
标识
DOI:10.1182/blood.2026034099
摘要
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy that may result in major bleeding events and reduction of chemotherapy relative dose intensity. While there remain no widely available licensed therapies to manage CIT, major studies-including global pivotal phase 3 clinical trials of the thrombopoietin receptor agonists (TPO-RAs) romiplostim and avatrombopag in CIT- have been completed, along with additional supporting evidence from other clinical trials and observational studies. Like patients with chemotherapy-induced neutropenia, not all patients with CIT require treatment-but for those who do, it can have a major impact on a patient's oncologic care and outcomes. Proper management of CIT requires an understanding of the two clinical subtypes of CIT (persistent and nadir), the limited role of platelet transfusions and antifibrinolytics, and when and how to appropriately use TPO-RA support. In this article, 4 patient cases of CIT are used to illustrate common and challenging scenarios occurring in clinical practice. Built on a framework of published studies and supported by extensive clinical experience, appropriate treatment strategies for CIT are described in detail, with emphasis on proper patient selection, dosing, titration, and monitoring for the use of TPO-RAs in CIT.
科研通智能强力驱动
Strongly Powered by AbleSci AI